According to a recent LinkedIn post from Xeltis, the company’s team plans to participate in the Vascular Access Society of the Americas 2026 Vascular Access for Dialysis Symposium in Salt Lake City, Utah. The post notes that Key Opinion Leader Dr. Jason K. Wagner is expected to present on the benefits of aXess, Xeltis’ restorative vascular access conduit for hemodialysis.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post indicates that Wagner’s session will cover 12‑month EU pivotal data that the company suggests demonstrate the potential of aXess, along with an update on an ongoing U.S. pivotal study. This emphasis on clinical evidence may be relevant for investors tracking the de‑risking of Xeltis’ pipeline and the progress of its regulatory and commercialization roadmap in both European and U.S. markets.
The LinkedIn content also lists several senior leaders and clinical specialists who are slated to represent Xeltis at the event, including the CEO, CMO, and U.S. clinical affairs personnel. Their presence could signal an effort to deepen relationships with vascular access specialists and payers, which may support future market adoption if aXess progresses toward approval and broader clinical use.
By aligning with a major vascular access symposium and positioning aXess within an “innovation/best abstracts” session, the post suggests Xeltis is seeking visibility among global experts focused on dialysis access challenges. For investors, this activity may indicate continued strategic investment in clinical development and physician engagement in a competitive hemodialysis access market.